About 65LAB

Channelling Global Expertise to Create Impactful Companies

65LAB was founded to turn innovations into lifesaving medicines. Our mission is to drive
scientific advancement and create new therapeutic companies from Singapore. 

We accelerate the drug discovery pathway and new company formation by bringing together
the expertise of global partners — leading research institutions in Singapore, established life science investors, and reputed drug discovery and development company Evotec.

65 pays homage to the year Singapore became an independent nation. It is also Singapore’s country code.

What’s the Process?

65LAB identifies promising therapeutic projects from applicants in partner academic and research institutions. It then provides project funding and mentoring to successful applicants
to achieve preclinical proof-of-concept.

65LAB’s drug discovery Expert in Residence (EIR) from Evotec will work closely with successful applicants to develop a commercialisation strategy and the necessary work plan. Project funding will depend on the envisaged milestones and can be an amount of up to USD 1.5 million.

Upon conclusion of 65LAB funding, a project may be selected for further development and inclusion in a future spinout. The 65LAB investors will then help to develop the subsequent business case and could form the syndicate to lead and/or participate in the spinout’s initial and subsequent financing rounds.

Expert in Residence

Stephen D. Hess, Ph.D.

Stephen brings over 30 years of experience in successful drug discovery to Singapore as Evotec’s Expert in Residence for 65LAB. He works closely with 65LABs academic institutions and investors to identify novel academic drug discovery opportunities suitable for 65LAB support, with a view to creating and growing innovative new biotech companies in Singapore.

Stephen has held senior scientific roles at Evotec in Hamburg, Germany since 2012, including Research Leader in the In Vitro Pharmacology department where he focused on integrated drug discovery collaborations. Prior to Evotec, Stephen’s drug discovery and assay development experience spans roles at Millipore, Invitrogen, Merck & Co and SIBIA Neurosciences in the US. Stephen has worked across multiple disease areas over the course of his career, including neurodegenerative disease, pain and immune disorders. He has also supported the progression of therapeutic candidates into late-stage clinical trials, and has particular expertise in ion channels and GPCRs. Stephen obtained a BS in Zoology, and MS and PhD in Biology, and undertook postdoctoral studies in the US.


Steering Committee